Benitec Biopharma (BNTC) · BB-301
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: 2H-2026
Benitec remains on track to provide updated interim clinical study results for Cohort 1 patients and Cohort 2 patients in 2H-2026.
EX-99.1 · filed · SEC filing
After
Stated timing: October 27-30, 2026
Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients, at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany, October 27-30, 2026.
EX-99.1 · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/BNTC-bb-301-2026-10-05, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/BNTC-bb-301-2026-10-05
Benitec Biopharma (BNTC) pipeline and stated timing · Calendar · Companies A–Z